Skip to main content
. 2023 Jul 5;49(7):831–839. doi: 10.1007/s00134-023-07141-5

Fig. 2.

Fig. 2

Long-term survival in patients with moderate or severe traumatic brain injury and treated with erythropoietin (EPO) or placebo [hazard ratio EPO vs placebo 0.73, 95% confidence interval 0.47–1.14)